Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

BACKGROUND: EGFR overexpression occurs in 27–55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagogastric adenocarcinoma. ME...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Waddell, Tom, Chau, Ian, Cunningham, David, Gonzalez, David, Okines, Alicia Frances Clare, Wotherspoon, Andrew, Saffery, Claire, Middleton, Gary, Wadsley, Jonathan, Ferry, David, Mansoor, Wasat, Crosby, Tom, Coxon, Fareeda, Smith, David, Waters, Justin, Iveson, Timothy, Falk, Stephen, Slater, Sarah, Peckitt, Clare, Barbachano, Yolanda
Formato: Artigo
Idioma:Inglês
Publicado em: Lancet Pub. Group 2013
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3669518/
https://ncbi.nlm.nih.gov/pubmed/23594787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70096-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados